Explore the published findings for tirzepatide, including Mounjaro and Zepbound.
54 cited sources193 recorded findingsStudy findings updated
AI-assisted research summary. These summaries are for general information. Read the original source for the full study and its limitations.
THE SHORT VERSION
What’s worth knowing.
The key findings, what they mean, and the context that matters.
THE HEADLINE TAKEAWAY-19.28%
Tirzepatide produced substantial weight loss versus placebo
In a network meta-analysis of randomized trials, tirzepatide's placebo-adjusted percentage weight loss was 19.28%.
This result applies to adults with overweight or obesity without diabetes. Head-to-head evidence was limited, and residual uncertainty remained.
See the evidence
Percentage weight loss with tirzepatide versus placebo among adults with overweight or obesity without diabetes in a network meta-analysis of randomized trials; head-to-head evidence was limited and residual uncertainty remained.
-19.28% 95% CI: -20.39% to -18.16%
Chen, Deshi et al.. Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.. BMJ medicine. 2026.
Tirzepatide outperformed semaglutide for weight loss
-20.2% vs -13.7%
In an open-label randomized trial, mean body-weight change at 72 weeks was -20.2% with tirzepatide versus -13.7% with semaglutide.
This was a phase 3b active-controlled trial included in a systematic review of obesity treatment. Real-world comparisons in the review were heterogeneous, with serious bias in several cohorts.
See the evidence
Mean weight change at 72 weeks with tirzepatide versus semaglutide in the included phase 3b open-label randomized active-controlled trial.
-20.2% vs -13.7%
Mohamed Abdalla, Samih Abdelmutalab et al.. Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review.. Cureus. 2026.
Adjusted weight-reduction advantage favoring tirzepatide over semaglutide in real-world cohorts; substantial heterogeneity precluded meta-analysis, and four cohorts were judged at serious risk of bias, principally because of unadjusted confounding.
Approximately 2.3-4.4 percentage points
Mohamed Abdalla, Samih Abdelmutalab et al.. Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review.. Cureus. 2026.
Weight regain followed tirzepatide cessation in pooled studies
13.04%
A subgroup meta-analysis estimated mean body-weight regain of 13.04% after tirzepatide cessation.
The tirzepatide subgroup contained 3 studies, and overall heterogeneity was high, so the pooled estimate has substantial between-study uncertainty.
See the evidence
Mean percentage body weight regain after tirzepatide cessation in the drug-class subgroup meta-analysis (k = 3); overall heterogeneity was high (I² = 97.6%).
13.04% 95% CI: 11.87-14.21
Patel, Henna et al.. Post-cessation Weight Regain After Weight Management Medications: A Systematic Review and Meta-Analysis.. Cureus. 2026.
Low-blood-pressure events rose while high-blood-pressure events fell
145%higher relative risk
Pooled randomized trials found that, versus control, tirzepatide had a 145% higher relative risk of low-blood-pressure adverse events but fewer high-blood-pressure adverse events.
Participants had type 2 diabetes or obesity. Absolute event rates are not available in this summary, and the higher-dose tirzepatide subgroup also had increased low-blood-pressure risk versus control.
See the evidence
145% higher relative risk, calculated from RR 2.45. This is not an absolute percentage-point difference.
Hypotension-related treatment-emergent adverse events with tirzepatide versus control in pooled randomized trials of patients with type 2 diabetes or obesity
RR 2.45 95% CI: 1.35-4.45
Chen, Qing-Xin et al.. Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis.. Endocrine. 2026.
Hypertension-related treatment-emergent adverse events with tirzepatide versus control in pooled randomized trials of patients with type 2 diabetes or obesity
RR 0.40 95% CI: 0.26-0.60
Chen, Qing-Xin et al.. Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis.. Endocrine. 2026.
Network trial evidence linked tirzepatide to lower mortality
28%lower relative odds
In randomized trials of type 2 diabetes medicines lasting at least 40 weeks, tirzepatide had 28% lower relative odds of all-cause mortality than placebo.
This network estimate may combine direct and indirect comparisons and is not an absolute-risk estimate. Separately, among patients with type 2 diabetes and atherosclerotic cardiovascular disease, an exploratory trial analysis did not establish a difference between tirzepatide and dulaglutide in the composite of cardiovascular death or heart-failure hospitalization/urgent visit.
See the evidence
28% lower relative odds, calculated from OR 0.72. This is not an absolute percentage-point difference.
All-cause mortality with tirzepatide versus placebo in the principal frequentist network meta-analysis of randomized trials lasting at least 40 weeks
OR 0.72 95% CI: 0.64-0.82
Silverii, Giovanni Antonio et al.. Effect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta-Analysis.. Diabetes, obesity & metabolism. 2026.
Exploratory SURPASS-CVOT analysis of the composite of cardiovascular death or HF hospitalization/urgent visit with tirzepatide versus dulaglutide, stratified by history of HF.
HR 0.85 with a history of HF; HR 0.96 without a history of HF 95% CI: 0.70-1.03 and 0.83-1.12, respectively
Nicholls, Stephen J et al.. Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis.. European journal of preventive cardiology. 2026.
Sleep-apnea remission occurred in many trial participants
Across the SURMOUNT-OSA phase 3 trials, 42%-50% of tirzepatide-treated patients met the study's remission definition; breathing-event frequency also fell versus placebo.
Remission meant fewer than 5 breathing events per hour, or fewer than 15 without symptoms. The figures come from a review of these trials.
See the evidence
Patients experiencing OSA disease remission with tirzepatide in the SURMOUNT-OSA phase 3 trials, defined as AHI below 5 events/hour or below 15 without symptoms
42%-50%
Harris, Alexandria et al.. Glucagon-Like Peptide-1 Receptor Agonists for Obstructive Sleep Apnea: A Review.. JAMA otolaryngology-- head & neck surgery. 2026.
Semaglutide ranked better for new atrial fibrillation than tirzepatide
43%lower relative risk
In a network meta-analysis, subcutaneous semaglutide had a 43% lower relative risk of new-onset atrial fibrillation than tirzepatide.
The analysis covered 94 randomized trials in diabetes or obesity. Arrhythmias were often not primary endpoints, events were limited, and network comparisons require confirmation.
Study details & original results
Barbosa, Lucas M et al.. Glucagon-Like Peptide-1 Receptor Agonists and Risk of Arrhythmias: A Network Meta-Analysis.. Heart rhythm. 2026.
New-onset atrial fibrillation incidence with subcutaneous semaglutide versus tirzepatide in a network meta-analysis of 94 RCTs involving patients with diabetes or obesity; further arrhythmia-focused studies are needed to confirm the finding.
RR 0.57 95% CI: 0.37-0.88
Network-meta-analysis ranking for reducing new-onset atrial fibrillation; this ranking is not an absolute or relative risk estimate, and the authors called for confirmatory arrhythmia-focused studies.
COPD flare-ups were lower than with two diabetes-drug comparators
27%lower relative hazard
In matched adults with chronic obstructive pulmonary disease and type 2 diabetes, tirzepatide was associated with a 27% lower relative hazard of an exacerbation than SGLT2 inhibitors; DPP-4 inhibitors gave a similar result.
The retrospective study had unequal median follow-up and possible residual confounding. Respiratory outcomes were similar with tirzepatide versus other GLP-1 receptor agonists, while mortality favored tirzepatide in that same comparison.
Study details & original results
Hsu, Wan-Hsuan et al.. Tirzepatide versus other glucose-lowering therapies and risk of COPD exacerbations in patients with comorbid type 2 diabetes: a retrospective cohort study.. Frontiers in pharmacology. 2026.
COPD exacerbation risk over days 1-365 with tirzepatide versus SGLT2 inhibitors among propensity-score-matched adults with COPD and type 2 diabetes; 6,080 patients per group, with median follow-up of 232 versus 365 days, respectively, in a retrospective cohort requiring randomized confirmation.
HR 0.73 95% CI: 0.64-0.82
COPD exacerbation risk over days 1-365 with tirzepatide versus DPP-4 inhibitors among propensity-score-matched adults with COPD and type 2 diabetes; 4,684 patients per group, with median follow-up of 235 versus 365 days, respectively, in a retrospective cohort requiring randomized confirmation.
HR 0.72 95% CI: 0.63-0.82
All-cause mortality over days 1-365 with tirzepatide versus other GLP-1 receptor agonists among propensity-score-matched adults with COPD and type 2 diabetes; 6,727 patients per group, with median follow-up of 233 versus 365 days, respectively. Other exacerbation and respiratory outcomes were similar, and randomized confirmation is needed.
HR 0.55 95% CI: 0.42-0.72
27% lower relative hazard, calculated from HR 0.73. This is not an absolute percentage-point difference.
Heart-failure benefit was reported, but comparison details are missing
A narrative review reported fewer cardiovascular deaths or worsening heart-failure events with tirzepatide in SUMMIT; the comparison group is not available in this summary.
The population for this estimate is also not available here. The narrative review lacked a systematic search and detailed risk-of-bias assessment.
Study details & original results
Jang, Rachelle et al.. GLP-1-based therapies in cardiovascular disease: outcomes, mechanisms, and emerging clinical applications.. European journal of clinical pharmacology. 2026.
Review-reported reduction in cardiovascular death or worsening heart failure with tirzepatide in the SUMMIT trial
Semaglutide or tirzepatide exposure was short in real-world records
Approximately 4.6 months
In observational electronic health-record cohorts of anti-obesity medicine users, median exposure to semaglutide or tirzepatide was approximately 4.6 months, versus 72 weeks typically required for peak trial benefit.
The electronic-record study was observational with variable follow-up. Among people with at least 72 weeks of tirzepatide exposure, substantial proportions did not reach weight-loss thresholds, but subgroup denominators were not reported.
Study details & original results
Ruan, Xiaoyang et al.. Current status of anti-obesity medications and performance, an EHR based survey.. BMC endocrine disorders. 2026.
Median real-world exposure duration for the two highlighted incretin-based AOMs, explicitly noted as substantially shorter than the 72 weeks typically required for peak RCT benefit.
Approximately 4.6 months
Target nonattainment among individuals after at least 72 weeks of tirzepatide exposure in the observational EHR cohorts; the abstract provided neither subgroup denominators nor confidence intervals.
Nearly 50% did not achieve 10% weight loss; nearly 25% did not achieve 5% weight loss
Magnitude reported for attenuation of weight regain with metformin co-therapy versus semaglutide or tirzepatide monotherapy; the abstract did not provide a tirzepatide-only estimate.
New-onset atrial fibrillation incidence with subcutaneous semaglutide versus tirzepatide in a network meta-analysis of 94 RCTs involving patients with diabetes or obesity; further arrhythmia-focused studies are needed to confirm the finding.
Network-meta-analysis ranking for reducing new-onset atrial fibrillation; this ranking is not an absolute or relative risk estimate, and the authors called for confirmatory arrhythmia-focused studies.
Hsu, Wan-Hsuan et al.. Tirzepatide versus other glucose-lowering therapies and risk of COPD exacerbations in patients with comorbid type 2 diabetes: a retrospective cohort study.. Frontiers in pharmacology. 2026.
COPD exacerbation risk over days 1-365 with tirzepatide versus SGLT2 inhibitors among propensity-score-matched adults with COPD and type 2 diabetes; 6,080 patients per group, with median follow-up of 232 versus 365 days, respectively, in a retrospective cohort requiring randomized confirmation.
COPD exacerbation risk over days 1-365 with tirzepatide versus DPP-4 inhibitors among propensity-score-matched adults with COPD and type 2 diabetes; 4,684 patients per group, with median follow-up of 235 versus 365 days, respectively, in a retrospective cohort requiring randomized confirmation.
All-cause mortality over days 1-365 with tirzepatide versus SGLT2 inhibitors among propensity-score-matched adults with COPD and type 2 diabetes; 6,080 patients per group, with median follow-up of 232 versus 365 days, respectively, in a retrospective cohort requiring randomized confirmation.
All-cause mortality over days 1-365 with tirzepatide versus DPP-4 inhibitors among propensity-score-matched adults with COPD and type 2 diabetes; 4,684 patients per group, with median follow-up of 235 versus 365 days, respectively, in a retrospective cohort requiring randomized confirmation.
All-cause mortality over days 1-365 with tirzepatide versus other GLP-1 receptor agonists among propensity-score-matched adults with COPD and type 2 diabetes; 6,727 patients per group, with median follow-up of 233 versus 365 days, respectively. Other exacerbation and respiratory outcomes were similar, and randomized confirmation is needed.
Jang, Rachelle et al.. GLP-1-based therapies in cardiovascular disease: outcomes, mechanisms, and emerging clinical applications.. European journal of clinical pharmacology. 2026.
Median real-world exposure duration for the two highlighted incretin-based AOMs, explicitly noted as substantially shorter than the 72 weeks typically required for peak RCT benefit.
Target nonattainment among individuals after at least 72 weeks of tirzepatide exposure in the observational EHR cohorts; the abstract provided neither subgroup denominators nor confidence intervals.
Added
Nearly 50% did not achieve 10% weight loss; nearly 25% did not achieve 5% weight lossSource [51]
All 3 findings from this source
Magnitude reported for attenuation of weight regain with metformin co-therapy versus semaglutide or tirzepatide monotherapy; the abstract did not provide a tirzepatide-only estimate.
Nicholls, Stephen J et al.. Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis.. European journal of preventive cardiology. 2026.
Exploratory SURPASS-CVOT analysis of the composite of all-cause death or HF hospitalization/urgent visit with tirzepatide versus dulaglutide among patients with type 2 diabetes and atherosclerotic cardiovascular disease, stratified by history of HF.
Added
HR 0.83 with a history of HF; HR 0.88 without a history of HF95% CI: 0.70-0.99 and 0.78-1.00, respectivelySource [49]
Exploratory SURPASS-CVOT analysis of the composite of cardiovascular death or HF hospitalization/urgent visit with tirzepatide versus dulaglutide, stratified by history of HF.
Added
HR 0.85 with a history of HF; HR 0.96 without a history of HF95% CI: 0.70-1.03 and 0.83-1.12, respectivelySource [49]
All 3 findings from this source
Exploratory SURPASS-CVOT analysis of MACE-3, defined as cardiovascular death, myocardial infarction, or stroke, with tirzepatide versus dulaglutide, stratified by history of HF.
Added
HR 0.90 with a history of HF; HR 0.93 without a history of HF95% CI: 0.76-1.08 and 0.83-1.04, respectivelySource [49]
SOURCE 504 findings
Dix, Sophie et al.. Real-World Treatment Patterns and Weight Outcomes Before and After a Tirzepatide Price Increase in Over One Million Self-Paying UK Adults With Overweight or Obesity.. Diabetes, obesity & metabolism. 2026.
Descriptive initiation mix among 1,033,522 self-paying adults treated through a single UK telehealth provider; this should not be interpreted as national market share.
Added
90.2% tirzepatide versus 9.8% semaglutideSource [50]
Interrupted-time-series estimate for semaglutide initiation in September 2025 relative to the projected pre-interruption trend, around the tirzepatide list-price increase of up to 170%.
Increase in tirzepatide-to-semaglutide switching around the September 2025 price interruption; the increase subsequently attenuated, and sensitivity analyses supported anticipatory changes in August.
Linear mixed-effects model estimates of 12-month weight loss among patients contributing follow-up at a single self-pay telehealth provider, with n=30,763 for tirzepatide and n=979 for semaglutide. These are observational within-treatment trajectories, not a reported randomized or adjusted between-treatment effect, and occurred with limited adjunctive lifestyle support.
Added
19.93% with tirzepatide; 16.40% with semaglutideTirzepatide 95% CI: 19.88%-19.98%; semaglutide 95% CI: 16.16%-16.64%Source [50]
SOURCE 486 findings
Eisa, Naseem et al.. Effects of tirzepatide (GIP/GLP-1 dual receptor agonist) on cardiorenal biomarkers and functional capacity in heart failure: a systematic review and meta-analysis.. The Journal of clinical endocrinology and metabolism. 2026.
Pooled hsCRP reduction with tirzepatide versus placebo or standard of care across six studies; heterogeneity was I2 = 0.0%, and the biomarker evidence was supported by moderate GRADE certainty.
Added
34.3% reduction95% CI: -38.4% to -30.1%Source [48]
Pooled NT-proBNP reduction with tirzepatide versus placebo or standard of care across three studies; heterogeneity was I2 = 58.1%, and the biomarker evidence was supported by moderate GRADE certainty.
KCCQ-CSS improvement with tirzepatide in the SUMMIT trial; the review characterized functional-outcome evidence as limited to a single trial and hypothesis-generating pending larger dedicated heart-failure trials.
Six-minute walk-test improvement with tirzepatide in the SUMMIT trial; the review characterized functional-outcome evidence as limited to a single trial and hypothesis-generating pending larger dedicated heart-failure trials.
Single-trial estimate of eGFR preservation with tirzepatide; the review characterized renal-outcome evidence as hypothesis-generating pending larger dedicated heart-failure trials.
Added
+2.90 mL/min/1.73 m²/year95% CI: 0.94 to 4.86Source [48]
Single-trial estimate of urine albumin-to-creatinine ratio reduction with tirzepatide; the review characterized renal-outcome evidence as hypothesis-generating pending larger dedicated heart-failure trials.
Added
25.0% reduction95% CI: -36.0% to -13.0%Source [48]
SOURCE 475 findings
Dziewierz, Artur et al.. Tirzepatide persistence, adherence, and dose escalation in a real-world setting with high out-of-pocket costs: a Polish cohort study.. Advances in medical sciences. 2026.
Escalation from an eligible low dose of 2.5 or 5 mg to at least 10 mg; the corresponding proportion was 18.6% when the full cohort was used as the denominator.
Added
565/2,194 (25.8%); 18.6% of the full cohortSource [47]
SOURCE 464 findings
Kuo, Chia-Yu et al.. Tirzepatide versus other anti-diabetic agents for the prevention of diabetic foot complications in patients with type 2 diabetes.. Frontiers in pharmacology. 2026.
Diabetic foot complications—a composite of ulcers, infections, critical limb ischemia, and revascularization or amputation—with tirzepatide versus sulfonylureas in propensity-score-matched adults with type 2 diabetes.
Diabetic foot complications with tirzepatide versus other GLP-1 receptor agonists in propensity-score-matched adults with type 2 diabetes; no statistically significant difference was found.
Sehtman-Shachar, Dvora R et al.. Kidney Outcomes With GLP-1 Receptor Agonists and Tirzepatide Versus Finerenone in Type 2 Diabetes and Chronic Kidney Disease: A Real-World Cohort Study.. Diabetes, obesity & metabolism. 2026.
Absolute risk difference for the composite kidney outcome with pooled GLP-1 receptor agonists or tirzepatide versus finerenone; the confidence interval included zero, so there was no evidence of an absolute-risk difference. Albuminuria was missing for most participants, creating potential residual confounding.
Added
-1.14 percentage points over 2.5 years95% CI: -2.45 to 0.17 percentage pointsSource [45]
Between-group difference in chronic annual eGFR slope over 0.5-2.5 years with pooled GLP-1 receptor agonists or tirzepatide versus finerenone; the confidence interval included zero. This observational estimate was not tirzepatide-specific, and missing baseline albuminuria may have produced residual confounding.
Added
-0.08 mL/min/1.73 m²/year95% CI: -1.27 to 1.12Source [45]
SOURCE 442 findings
Al-Nusair, Mohammed et al.. Cardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes.. Journal of diabetes and metabolic disorders. 2026.
Composite of acute myocardial infarction, stroke, and acute heart failure with tirzepatide versus semaglutide among propensity-score-matched patients with type 2 diabetes in a TriNetX observational study; the reported HR is internally inconsistent with its confidence interval.
Added
HR 0.9; incidence 4.6% vs 5.5%; ARD -0.9%HR 95% CI: 0.92-0.96; ARD 95% CI: -1.01 to -0.77Source [44]
All-cause mortality with tirzepatide versus semaglutide among propensity-score-matched patients with type 2 diabetes in a TriNetX observational study.
Added
HR 0.8; incidence 0.6% vs 0.9%; ARD -0.3%HR 95% CI: 0.74-0.84; ARD 95% CI: -0.33 to -0.24Source [44]
SOURCE 434 findings
Aronne, Louis J et al.. Evaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetes.. Obesity pillars. 2026.
Mean weight regain from nadir to week 176 in the post hoc analysis of tirzepatide-adherent SURMOUNT-1 participants with baseline prediabetes and at least 5% weight reduction at nadir.
Added
3.8 kg with 5 mg, 4.4 kg with 10 mg, and 3.7 kg with 15 mgSource [43]
Distribution of weight regain from nadir to week 176 across pooled tirzepatide doses in the selected adherent SURMOUNT-1 population.
Added
70% had <5% regain; 22% had 5% to <10% regain; 8% had ≥10% regainSource [43]
All 4 findings from this source
Prevalence of high waist-to-height ratio (>0.59) at baseline and at week 176 in the <5%, 5% to <10%, and ≥10% weight-regain groups, respectively.
Added
94% at baseline; 45%, 59%, and 68% at week 176Source [43]
Conversion from prediabetes to normoglycemia by week 176 among selected tirzepatide-treated participants, reported as occurring across weight-regain groups.
Rivera Gutierrez, Rene de J et al.. Cardiometabolic and atherosclerotic cardiovascular disease outcomes associated with tirzepatide: insights from a 1-year multicenter observational study.. Journal of the Endocrine Society. 2026.
Weight loss at 12 months among 1,028 adults with overweight or obesity selected for continuous weekly tirzepatide use for at least 12 months in a retrospective multicenter cohort.
Relative changes in cardiometabolic parameters after 12 months of continuous tirzepatide use in the retrospective cohort.
Added
Fasting glucose -19.5%; HbA1c -16.0%; triglycerides -8.5%; alanine aminotransferase -10.6%; HDL cholesterol +11.3%; all P < .001Source [42]
All 5 findings from this source
Overall change in estimated 10-year ASCVD risk—not observed cardiovascular events—among the 275 participants with complete baseline and 12-month data; the change was not statistically significant.
Changes in estimated 10-year ASCVD risk by achieved weight-loss category among 275 complete cases in the observational cohort; risk decreased significantly only in categories achieving at least 10% TBWL.
Change in estimated 10-year ASCVD risk classification among the 275 participants with complete baseline and 12-month data; these were modeled risk categories, not observed cardiovascular outcomes.
Added
Low-risk prevalence increased from 38.3% to 46.4% (P < .001); 11.7% transitioned from higher-risk categories to low riskSource [42]
SOURCE 416 findings
Ciudin, Andreea et al.. Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes.. International journal of obesity (2005). 2026.
BMI difference versus semaglutide 2.4 mg/week in the unadjusted placebo-anchored indirect comparison, for tirzepatide 10 and 15 mg/week respectively, among adults without type 2 diabetes.
Added
-1.87 kg/m2 with tirzepatide 10 mg; -2.37 kg/m2 with tirzepatide 15 mgReported intervals (type and level not specified in the abstract): -2.43 to -1.31; -2.93 to -1.81Source [41]
Greater diastolic blood-pressure decreases with each tirzepatide dose versus semaglutide 2.4 mg/week in the indirect treatment comparison.
Added
-1.90, -2.40, and -1.30 mmHg with tirzepatide 5, 10, and 15 mg, respectivelyReported intervals (type and level not specified in the abstract): -3.19 to -0.61; -3.69 to -1.11; -2.59 to -0.01Source [41]
All 6 findings from this source
Greater HDL increases with each tirzepatide dose versus semaglutide 2.4 mg/week in the indirect treatment comparison.
Added
+3.80%, +5.40%, and +5.00% with tirzepatide 5, 10, and 15 mg, respectivelyReported intervals (type and level not specified in the abstract): 1.23% to 6.37%; 2.83% to 7.97%; 2.43% to 7.57%Source [41]
Difference with tirzepatide 15 mg/week versus semaglutide 2.4 mg/week among the subset of participants reporting body-composition outcomes in the indirect treatment comparison.
Added
-3.50% percentage body fat massReported interval (type and level not specified in the abstract): -6.66% to -0.34%Source [41]
Difference with tirzepatide 15 mg/week versus semaglutide 2.4 mg/week among the subset of participants reporting body-composition outcomes in the indirect treatment comparison; this is a percentage body-composition measure, not evidence of increased absolute lean mass.
Added
+3.40% percentage body lean massReported interval (type and level not specified in the abstract): 0.40% to 6.40%Source [41]
Greater waist-circumference reduction versus semaglutide 2.4 mg in the unadjusted placebo-anchored indirect comparison among adults without type 2 diabetes; STEP 1 and SURMOUNT-1 were compared at weeks 68 and 72, respectively.
Added
-5.25 cm with tirzepatide 10 mg; -5.75 cm with tirzepatide 15 mgReported intervals (type and level not specified in the abstract): -6.69 to -3.81 cm and -7.19 to -4.31 cm, respectivelySource [41]
SOURCE 402 findings
Lin, Chih-Lang et al.. Tirzepatide versus GLP-1 receptor agonists and stroke in patients with atrial fibrillation and type 2 diabetes.. Nature communications. 2026.
One-year absolute difference in any-stroke risk favoring tirzepatide versus another GLP-1 receptor agonist among matched adults with atrial fibrillation and type 2 diabetes; this was a retrospective electronic health-record association, and randomized trials are required before treatment recommendations can change.
One-year absolute difference in all-cause mortality favoring tirzepatide versus another GLP-1 receptor agonist among matched adults with atrial fibrillation and type 2 diabetes; this was a retrospective electronic health-record association, and randomized trials are required before treatment recommendations can change.
AlAraibi, Ahmed J et al.. The effects of tirzepatide and semaglutide on clinical and metabolic outcomes in patients with heart failure with preserved ejection fraction and obesity: a systematic review and meta-analysis.. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2026.
Pooled improvement in KCCQ clinical summary score with semaglutide or tirzepatide among patients with HFpEF and obesity in the primary randomized-trial analysis.
Pooled improvement in 6-minute walk distance with semaglutide or tirzepatide among patients with HFpEF and obesity in the primary randomized-trial analysis.
Pooled risk of worsening heart-failure events with semaglutide or tirzepatide among patients with HFpEF and obesity in the primary randomized-trial analysis.
Tu, Cheng-Yun et al.. Association of tirzepatide versus Glucagon-Like Peptide-1 receptor agonists with oral and periodontal outcomes in patients with type 2 Diabetes: A Global propensity Score-Matched cohort study.. Diabetes research and clinical practice. 2026.
One-year mortality with tirzepatide versus GLP-1 receptor agonists among propensity-score-matched adults with type 2 diabetes; retrospective EHR association subject to low recorded event rates and requiring prospective confirmation.
One-year recorded periodontitis risk with tirzepatide versus GLP-1 receptor agonists among propensity-score-matched adults with type 2 diabetes; retrospective EHR association with low recorded event rates and no systematic dental assessment.
One-year recorded tooth-extraction risk with tirzepatide versus GLP-1 receptor agonists among propensity-score-matched adults with type 2 diabetes; retrospective EHR association with low recorded event rates and no systematic dental assessment.
One-year recorded peri-implant complication risk with tirzepatide versus GLP-1 receptor agonists among propensity-score-matched adults with type 2 diabetes; retrospective EHR association with low recorded event rates and no systematic dental assessment.
One-year recorded periodontal-procedure risk with tirzepatide versus GLP-1 receptor agonists among propensity-score-matched adults with type 2 diabetes; retrospective EHR association with low recorded event rates and no systematic dental assessment.
One-year recorded oral or maxillofacial infection risk with tirzepatide versus GLP-1 receptor agonists among propensity-score-matched adults with type 2 diabetes; retrospective EHR association with low recorded event rates and no systematic dental assessment.
One-year composite recorded oral/periodontal outcome with tirzepatide versus GLP-1 receptor agonists among propensity-score-matched adults with type 2 diabetes; results were directionally consistent across additional analyses, but low recorded event rates and retrospective EHR limitations require prospective confirmation.
Waki, Hironori et al.. Changes in Abdominal Adiposity and Associations With Metabolic Health Markers Following Tirzepatide in Japanese Participants With Obesity Disease: Results From the SURMOUNT-J Study.. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2026.
Post hoc correlations at week 72 between weight or visceral adipose tissue reductions and reductions in glucose, insulin, and C-peptide AUC during oral glucose tolerance testing
Mohamed Abdalla, Samih Abdelmutalab et al.. Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review.. Cureus. 2026.
Adjusted weight-reduction advantage favoring tirzepatide over semaglutide in real-world cohorts; substantial heterogeneity precluded meta-analysis, and four cohorts were judged at serious risk of bias, principally because of unadjusted confounding.
Added
Approximately 2.3-4.4 percentage pointsSource [36]
SOURCE 353 findings
Scavone, Cristina et al.. Reporting patterns of suicide- and self-injury-related events involving liraglutide, semaglutide, and tirzepatide: data from the European pharmacovigilance database.. Frontiers in pharmacology. 2026.
Reported suicide/self-injury cases among 42,941 eligible EudraVigilance reports from 2021 through 2025. These are spontaneous-report counts, not incidence estimates, and do not establish causality.
Reporting frequency of suicide/self-injury events with liraglutide versus tirzepatide. This is a spontaneous-report disproportionality comparison, not an estimate of clinical incidence or causal risk, and is subject to pharmacovigilance-reporting limitations.
Reporting frequency of suicide/self-injury events with semaglutide versus tirzepatide. This is a spontaneous-report disproportionality comparison, not an estimate of clinical incidence or causal risk, and is subject to pharmacovigilance-reporting limitations.
Santos-Pereira, Mariana et al.. Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery - a systematic review and meta-analysis.. Frontiers in endocrinology. 2026.
At 6 months, tirzepatide was favored over semaglutide for total weight loss among adults treated at least one year after metabolic bariatric surgery; the authors cautioned that substantial heterogeneity across studies requires cautious interpretation.
Patel, Krishan S et al.. Comparative outcomes for tirzepatide versus glucagon-like peptide-1 receptor agonists in patients with inflammatory bowel disease: a national propensity matched study.. Intestinal research. 2026.
Risk of intravenous steroid use over 18 months with tirzepatide versus GLP-1 receptor agonists in propensity-matched adults with inflammatory bowel disease.
Risk of the composite outcome of intravenous steroid use and intestinal surgery over 18 months with tirzepatide versus GLP-1 receptor agonists in propensity-matched adults with inflammatory bowel disease.
Risk of intravenous steroid use with tirzepatide versus GLP-1 receptor agonists in the ulcerative colitis subgroup of the propensity-matched observational study.
Hageen, Ahmed W et al.. Efficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta-Analysis of Randomized Clinical Trials.. Endocrinology, diabetes & metabolism. 2026.
Tirzepatide 1 mg produced 4.39 kg less Week 16 body-weight reduction than tirzepatide 5 mg. Interpret cautiously because several comparisons were indirect, many participants had not reached maintenance dose, one trial contributed most participants, and significant inconsistency was observed for early body-weight outcomes.
Dulaglutide 0.75 mg produced 3.10 kg less Week 16 body-weight reduction than tirzepatide 5 mg. Interpret cautiously because several comparisons were indirect, many participants had not reached maintenance dose, one trial contributed most participants, and significant inconsistency was observed for early body-weight outcomes.
Additional Week 24 HbA1c reduction with tirzepatide 15 mg versus 5 mg. Interpret cautiously because several comparisons were indirect, many participants had not reached maintenance dose, and one trial contributed 13,165 of 14,348 participants.
Added
MD -0.40 percentage points95% CI: -0.62 to -0.19Source [30]
Additional Week 24 HbA1c reduction with tirzepatide 10 mg versus 5 mg. Interpret cautiously because several comparisons were indirect, many participants had not reached maintenance dose, and one trial contributed most participants.
Added
MD -0.23 percentage points95% CI: -0.44 to -0.02Source [30]
Dulaglutide 1.5 mg produced 0.67 percentage points less Week 24 HbA1c reduction than tirzepatide 5 mg. Interpret cautiously because several comparisons were indirect, many participants had not reached maintenance dose, and one trial contributed most participants.
Added
MD 0.67 percentage points95% CI: 0.25 to 1.09Source [30]
SOURCE 314 findings
Liao, Kuang-Ming et al.. Tirzepatide and the risk of asthma exacerbations in patients with type 2 diabetes.. Frontiers in endocrinology. 2026.
No statistically significant difference in acute asthma exacerbation risk between tirzepatide and SGLT2 inhibitors among propensity-score-matched adults with asthma and type 2 diabetes (P = .064)
No statistically significant difference in acute asthma exacerbation risk between tirzepatide and GLP-1 receptor agonists among propensity-score-matched adults with asthma and type 2 diabetes (P = .49)
Mansouri, Ensieh S et al.. Tirzepatide and the Incidence of Atrial Fibrillation in Adults With Overweight or Obesity: An Updated Meta-Analysis of Randomized Controlled Trials.. Journal of the American Heart Association. 2026.
Atrial fibrillation with tirzepatide versus placebo among adults with overweight or obesity in a Bayesian meta-analysis of 10 RCTs; no significant association was found.
Atrial arrhythmia with tirzepatide versus placebo among adults with overweight or obesity in a Bayesian meta-analysis of 10 RCTs; no significant association was found.
Any arrhythmia with tirzepatide versus placebo among adults with overweight or obesity in a Bayesian meta-analysis of 10 RCTs; odds were higher, but event rates were low and the authors advised cautious interpretation.
Patients experiencing OSA disease remission with tirzepatide in the SURMOUNT-OSA phase 3 trials, defined as AHI below 5 events/hour or below 15 without symptoms
Chen, Deshi et al.. Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.. BMJ medicine. 2026.
Percentage weight loss with tirzepatide versus placebo among adults with overweight or obesity without diabetes in a network meta-analysis of randomized trials; head-to-head evidence was limited and residual uncertainty remained.
Moiz, Areesha et al.. Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.. Annals of internal medicine. 2026.
Adults with overweight or obesity without diabetes receiving tirzepatide in an updated systematic review of RCTs; this was reported as an “up to” estimate, and heterogeneity precluded quantitative synthesis.
Added
-19.0% placebo-subtracted weight loss95% CI: -21.6% to -16.4%Source [25]
SOURCE 264 findings
Kow, Chia Siang et al.. Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-Analysis.. Endocrinology, diabetes & metabolism. 2026.
Linear-model projection for regaining 50% of initial weight loss after semaglutide or tirzepatide discontinuation; observed follow-up was 4-52 weeks, and longer-term estimates were model-based extrapolations
Linear-model projection for return to baseline weight after semaglutide or tirzepatide discontinuation; observed follow-up was 4-52 weeks, and longer-term estimates were model-based extrapolations
Falcon, Beverly et al.. Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSA.. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2026.
Descriptive, hypothesis-generating post hoc analyses of two 52-week phase 3 trials among adults with moderate-to-severe OSA and obesity receiving maximum-tolerated-dose tirzepatide; these are subgroup ranges rather than formal interaction-test results.
Added
AHI reductions by baseline subgroup: age, -27.7 to -34.1 events/h; sex, -19.8 to -32.6 events/h; AHI severity, -12.1 to -52.2 events/h; BMI, -25.2 to -34.4 events/h; neck circumference, -23.9 to -30.8 events/hSource [27]
SOURCE 241 finding
Galindo, Rodolfo J et al.. Glycemia-based predictors of T2D development in adults with obesity and prediabetes: SURMOUNT-1 post hoc analysis.. Journal of the Endocrine Society. 2026.
Tirzepatide-associated reduction in new-onset type 2 diabetes versus placebo among adults with obesity and prediabetes in the 3-year SURMOUNT-1 post hoc analysis, using high-risk and standard-risk classifications based on three exploratory glycemia criteria; the abstract reported ranges only and no interaction test.
Added
90%-99% reduction in high-risk groups; 68%-91% reduction in standard-risk groupsSource [24]
SOURCE 232 findings
Upadhyay, Navneet et al.. Trends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis.. Diabetes, obesity & metabolism. 2026.
Difference-in-differences estimate for all-cause healthcare costs, excluding tirzepatide, during months 12-18 among adults older than 55 years without type 2 diabetes initiating tirzepatide versus propensity-score-matched untreated controls.
Added
DiD -$319 per person per month (25.4% reduction; p=0.015)95% CI: -$544 to -$94Source [23]
Incidence of inpatient/emergency department visits during months 12-18 with tirzepatide versus matched untreated controls.
Clift, Ashley Kieran et al.. Weight loss outcomes with tirzepatide in women with and without self-reported polycystic ovary syndrome.. Journal of the Endocrine Society. 2026.
Mean weight change at 10 months among tirzepatide-treated women with self-reported PCOS versus women without PCOS; the difference was not statistically significant, with only 40 women with PCOS reaching this time point.
Added
-19.40% vs -18.74%PCOS: 95% CI: -22.38% to -16.42%; without PCOS: 95% CI: -19.67% to -17.81%Source [22]
Kaplan-Meier-estimated proportion of tirzepatide-treated women with self-reported PCOS attaining at least 20% total body weight loss by 10 months.
Observational association between greater digital engagement and additional absolute weight loss by 10 months among tirzepatide-treated women with self-reported PCOS; P < .001.
Added
3.42% more weight loss95% CI: 1.71%-5.12%Source [22]
SOURCE 204 findings
Banerjee, Mainak et al.. Major Adverse Liver Outcomes With Tirzepatide and Injectable Semaglutide in Adults With Overweight or Obesity and Type 2 Diabetes.. Obesity (Silver Spring, Md.). 2026.
Major adverse liver outcomes with tirzepatide versus injectable semaglutide in propensity-matched adults with overweight or obesity and type 2 diabetes over a median follow-up of approximately 17 months; estimated incidence rates were 4.05 versus 4.04 per 1000 person-years, with no significant difference.
Major adverse liver outcomes with tirzepatide versus injectable semaglutide among the subgroup with MASLD; incidence rates were 9.97 versus 10.03 per 1000 person-years, consistent with the primary analysis.
Major adverse liver outcomes with tirzepatide versus injectable semaglutide in the as-treated sensitivity analysis, consistent with the primary analysis.
Greater BMI reduction with tirzepatide than with injectable semaglutide in the observational target-trial emulation.
Added
Mean BMI difference approximately 1.1 kg/m²; p<0.001Source [20]
SOURCE 215 findings
Xu, Ying et al.. Efficacy and safety of different once-weekly glucagon-like peptide-1 receptor agonists-A systematic review and Bayesian network meta-analysis.. Diabetes research and clinical practice. 2025.
Change from baseline to endpoint in HbA1c with tirzepatide 15 mg versus placebo in a Bayesian network meta-analysis of once-weekly agents.
Added
MD -1.4%Reported interval: -1.6% to -1.2%; interval type and level not specified in the abstractSource [21]
Greater weight loss with tirzepatide 15 mg versus other once-weekly GLP-1RAs in the Bayesian network meta-analysis; the abstract did not report the units.
Added
MD -8.7; units not specified in the abstractReported interval: -10 to -6.8; interval type and level not specified in the abstractSource [21]
All 5 findings from this source
Greater systolic blood-pressure reduction with tirzepatide 15 mg versus other once-weekly GLP-1RAs in the Bayesian network meta-analysis; the abstract did not report the units.
Added
MD -4.8; units not specified in the abstractReported interval: -8.2 to -1.4; interval type and level not specified in the abstractSource [21]
Higher nausea risk reported for tirzepatide 15 mg in the Bayesian network comparison; the abstract does not separately identify the odds ratio's reference treatment.
Added
OR 6.4Reported interval: 4.3-9.6; interval type and level not specified in the abstractSource [21]
Higher diarrhea risk reported for tirzepatide 15 mg in the Bayesian network comparison; the abstract does not separately identify the odds ratio's reference treatment.
Added
OR 3.5Reported interval: 2.5-5.2; interval type and level not specified in the abstractSource [21]
SOURCE 195 findings
Loblundo, Cali et al.. Glucagon-Like Peptide-1 Receptor Agonists for Obstructive Sleep Apnea With and Without Continuous Positive Airway Pressure.. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2026.
Apnea-hypopnea index with pooled liraglutide or tirzepatide versus controls in obstructive sleep apnea; the authors reported that the effect was independent of continuous positive airway pressure use.
Added
Mean difference -12.4 events/hour; P<.0000195% CI: -17.2 to -7.7Source [19]
Body-weight change with pooled liraglutide or tirzepatide versus controls among patients with obstructive sleep apnea.
Hypertension-related treatment-emergent adverse events with tirzepatide versus control in pooled randomized trials of patients with type 2 diabetes or obesity
Hypotension-related treatment-emergent adverse events with tirzepatide versus control in pooled randomized trials of patients with type 2 diabetes or obesity
Sattar, Naveed et al.. Achieving the triple endpoint of body weight reduction thresholds, systolic blood pressure reduction ≥5 mmHg and non-HDL cholesterol <130 mg/dL with tirzepatide in people with obesity: A post hoc analysis from the SURMOUNT trials.. PloS one. 2026.
Across-trial range for tirzepatide versus placebo achieving the triple endpoint of at least 5% body weight reduction, at least 5 mmHg systolic blood pressure reduction, and non-HDL-C below 130 mg/dL at the primary endpoint of each SURMOUNT trial.
Statistical significance of the between-treatment odds ratios for the triple-endpoint proportions across the SURMOUNT trials; numerical odds ratios were not provided in the abstract.
Gibble, Theresa Hunter et al.. Tirzepatide Persistence and Associated Changes in Clinical Outcomes in US Adults With Obesity or Overweight: A 6-Month Claims Database Analysis.. Diabetes, obesity & metabolism. 2026.
Persistence during 6 months after tirzepatide initiation among 22,512 commercially insured US adults with obesity or overweight and without type 2 diabetes
Su, Yu-Jung et al.. Tirzepatide Use Is Associated with Reduced Risk of Carpal Tunnel Syndrome in Overweight and Obese Adults.. Clinical pharmacology and therapeutics. 2026.
Khalil, Ibrahim et al.. Superior Cardiorenal Protection With Tirzepatide Over Dulaglutide in Heart Failure With Preserved Ejection Fraction: A Large-Scale Propensity Score-Matched Real-World Analysis.. Clinical cardiology. 2026.
Sattar, Naveed et al.. Predicted 10-Year Cardiovascular Disease Risk Reduction with Tirzepatide Use Over Three Years for Primary Prevention of Cardiovascular Disease in Obesity.. European journal of preventive cardiology. 2026.
Week 72 change from baseline in Framingham-predicted 10-year CVD risk with tirzepatide 15 mg versus placebo in the post hoc SURMOUNT-1 primary-prevention analysis; these were predicted risks, not observed cardiovascular events.
Added
Tirzepatide ARR -1.92% vs placebo ARI 1.10%; p<0.001Source [15]
Model-derived treatment-effect HR for Framingham-predicted 10-year CVD risk at week 72 with tirzepatide 15 mg versus placebo; this was not an HR based on observed cardiovascular events.
Week 176 change from baseline in Framingham-predicted 10-year CVD risk among tirzepatide-treated participants versus placebo in the post hoc SURMOUNT-1 primary-prevention analysis; these were predicted risks, not observed cardiovascular events.
Added
Tirzepatide ARR -1.31% vs placebo ARI 3.84%; p<0.001Source [15]
Model-derived treatment-effect HR for Framingham-predicted 10-year CVD risk at week 176 with tirzepatide versus placebo; this was not an HR based on observed cardiovascular events.
Rosenior-Patten, Onayomi et al.. Real-World Effectiveness and Treatment Patterns of Tirzepatide in a Large UK Digital Health Cohort.. Diabetes, obesity & metabolism. 2026.
Silverii, Giovanni Antonio et al.. Effect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta-Analysis.. Diabetes, obesity & metabolism. 2026.
Mean percentage body weight regain after tirzepatide cessation in the drug-class subgroup meta-analysis (k = 3); overall heterogeneity was high (I² = 97.6%).
Hwang, Inyoung et al.. Real-World Comparative Weight Loss of GLP-1 Receptor Agonists in the All of Us Research Program: A Retrospective Cohort Study.. Drug design, development and therapy. 2026.
Adjusted relative likelihood of achieving at least 15% weight loss with tirzepatide versus liraglutide among adults with obesity; observational analysis with possible residual confounding, a tirzepatide sample of 386, and limited follow-up.
Mean weight change at 12 months among tirzepatide initiators with obesity; observational analysis with possible residual confounding, a tirzepatide sample of 386, and limited follow-up.
Mortada, Ibrahim et al.. Association of Tirzepatide Use With Clinical Outcomes After TAVR in Obese Patients: A Propensity Score-Matched Real-World Study.. Journal of the Society for Cardiovascular Angiography & Interventions. 2026.
Kamrul-Hasan, A B M et al.. Comparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis.. Endocrinology, diabetes & metabolism. 2026.
Tirzepatide 15 mg or maximum tolerated dose in adults with obesity without diabetes
Added
18.04% greater reduction in body weight versus placebo; p<0.0000195% CI: -19.86 to -16.22Source [6]
Exploratory indirect comparison of percentage weight loss across Asian and predominantly non-Asian trial populations; the analysis cannot establish equivalence
Added
-18.16% in Asian trials versus -17.92% in predominantly non-Asian trials; p=0.94Source [6]
SOURCE 077 findings
Azzam, Ahmed Y et al.. Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation.. JACC. Advances. 2026.
Zeng, Lijuan et al.. Respiratory Adverse Events of Weight-Loss Drugs: A Systematic Review and Meta-Analysis.. Annals of the American Thoracic Society. 2026.
Wu, Jheng-Yan et al.. Comparative Cardiovascular Outcomes of Tirzepatide and Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.. Journal of the American Heart Association. 2026.
Kahkedjian, Fredy et al.. Tirzepatide and reduced risk of pulmonary embolism and deep vein thrombosis: a multicenter U.S. cohort study.. Frontiers in endocrinology. 2026.
Kitsunai, Hiroya et al.. Real-world clinical outcomes of tirzepatide administration in older patients with type 2 diabetes, with a focus on the risk of hypoglycemia and weight loss-related parameters.. Endocrine journal. 2026.
Ahmed, Faizan et al.. GLP-1 Receptor Agonists or Dual GLP-1/GIP Receptor Agonists vs. SGLT2 Inhibitors in Patients with Atrial Fibrillation and HFpEF: A Propensity-Matched Real-World Analysis.. Journal of clinical medicine. 2026.
Browse the 54 original sourcesThe full bibliography behind this monitor.
[1]
Kitsunai, Hiroya et al.. Real-world clinical outcomes of tirzepatide administration in older patients with type 2 diabetes, with a focus on the risk of hypoglycemia and weight loss-related parameters.. Endocrine journal. 2026.
Ahmed, Faizan et al.. GLP-1 Receptor Agonists or Dual GLP-1/GIP Receptor Agonists vs. SGLT2 Inhibitors in Patients with Atrial Fibrillation and HFpEF: A Propensity-Matched Real-World Analysis.. Journal of clinical medicine. 2026.
Kahkedjian, Fredy et al.. Tirzepatide and reduced risk of pulmonary embolism and deep vein thrombosis: a multicenter U.S. cohort study.. Frontiers in endocrinology. 2026.
Wu, Jheng-Yan et al.. Comparative Cardiovascular Outcomes of Tirzepatide and Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.. Journal of the American Heart Association. 2026.
Zeng, Lijuan et al.. Respiratory Adverse Events of Weight-Loss Drugs: A Systematic Review and Meta-Analysis.. Annals of the American Thoracic Society. 2026.
Kamrul-Hasan, A B M et al.. Comparative Efficacy and Safety of Tirzepatide in Asian and Non-Asian Adults With Obesity Without Diabetes: A Systematic Review and Meta-Analysis.. Endocrinology, diabetes & metabolism. 2026.
Azzam, Ahmed Y et al.. Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: A Target Trial Emulation.. JACC. Advances. 2026.
Mortada, Ibrahim et al.. Association of Tirzepatide Use With Clinical Outcomes After TAVR in Obese Patients: A Propensity Score-Matched Real-World Study.. Journal of the Society for Cardiovascular Angiography & Interventions. 2026.
Hwang, Inyoung et al.. Real-World Comparative Weight Loss of GLP-1 Receptor Agonists in the All of Us Research Program: A Retrospective Cohort Study.. Drug design, development and therapy. 2026.
Silverii, Giovanni Antonio et al.. Effect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta-Analysis.. Diabetes, obesity & metabolism. 2026.
Rosenior-Patten, Onayomi et al.. Real-World Effectiveness and Treatment Patterns of Tirzepatide in a Large UK Digital Health Cohort.. Diabetes, obesity & metabolism. 2026.
Su, Yu-Jung et al.. Tirzepatide Use Is Associated with Reduced Risk of Carpal Tunnel Syndrome in Overweight and Obese Adults.. Clinical pharmacology and therapeutics. 2026.
Khalil, Ibrahim et al.. Superior Cardiorenal Protection With Tirzepatide Over Dulaglutide in Heart Failure With Preserved Ejection Fraction: A Large-Scale Propensity Score-Matched Real-World Analysis.. Clinical cardiology. 2026.
Sattar, Naveed et al.. Predicted 10-Year Cardiovascular Disease Risk Reduction with Tirzepatide Use Over Three Years for Primary Prevention of Cardiovascular Disease in Obesity.. European journal of preventive cardiology. 2026.
Gibble, Theresa Hunter et al.. Tirzepatide Persistence and Associated Changes in Clinical Outcomes in US Adults With Obesity or Overweight: A 6-Month Claims Database Analysis.. Diabetes, obesity & metabolism. 2026.
Sattar, Naveed et al.. Achieving the triple endpoint of body weight reduction thresholds, systolic blood pressure reduction ≥5 mmHg and non-HDL cholesterol <130 mg/dL with tirzepatide in people with obesity: A post hoc analysis from the SURMOUNT trials.. PloS one. 2026.
Loblundo, Cali et al.. Glucagon-Like Peptide-1 Receptor Agonists for Obstructive Sleep Apnea With and Without Continuous Positive Airway Pressure.. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2026.
Banerjee, Mainak et al.. Major Adverse Liver Outcomes With Tirzepatide and Injectable Semaglutide in Adults With Overweight or Obesity and Type 2 Diabetes.. Obesity (Silver Spring, Md.). 2026.
Xu, Ying et al.. Efficacy and safety of different once-weekly glucagon-like peptide-1 receptor agonists-A systematic review and Bayesian network meta-analysis.. Diabetes research and clinical practice. 2025.
Clift, Ashley Kieran et al.. Weight loss outcomes with tirzepatide in women with and without self-reported polycystic ovary syndrome.. Journal of the Endocrine Society. 2026.
Upadhyay, Navneet et al.. Trends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis.. Diabetes, obesity & metabolism. 2026.
Galindo, Rodolfo J et al.. Glycemia-based predictors of T2D development in adults with obesity and prediabetes: SURMOUNT-1 post hoc analysis.. Journal of the Endocrine Society. 2026.
Moiz, Areesha et al.. Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes : An Updated Systematic Review.. Annals of internal medicine. 2026.
Kow, Chia Siang et al.. Weight Regain Trajectories After Discontinuation of Semaglutide or Tirzepatide: A Reconstructed Aggregate-Data Bayesian Longitudinal Meta-Analysis.. Endocrinology, diabetes & metabolism. 2026.
Falcon, Beverly et al.. Association of tirzepatide with changes in OSA-related measures based on baseline characteristics - post hoc analyses of SURMOUNT-OSA.. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2026.
Chen, Deshi et al.. Comparative efficacy and safety of glucagon-like peptide 1 based drugs for weight loss in adults with overweight or obesity without diabetes: network meta-analysis of randomised controlled trials.. BMJ medicine. 2026.
Hageen, Ahmed W et al.. Efficacy and Safety of Tirzepatide Versus Dulaglutide in Type 2 Diabetes With or Without Established Atherosclerotic Cardiovascular Disease: A Network Meta-Analysis of Randomized Clinical Trials.. Endocrinology, diabetes & metabolism. 2026.
Mansouri, Ensieh S et al.. Tirzepatide and the Incidence of Atrial Fibrillation in Adults With Overweight or Obesity: An Updated Meta-Analysis of Randomized Controlled Trials.. Journal of the American Heart Association. 2026.
Santos-Pereira, Mariana et al.. Use of incretin receptor agonists in patients submitted to metabolic bariatric surgery - a systematic review and meta-analysis.. Frontiers in endocrinology. 2026.
Patel, Krishan S et al.. Comparative outcomes for tirzepatide versus glucagon-like peptide-1 receptor agonists in patients with inflammatory bowel disease: a national propensity matched study.. Intestinal research. 2026.
Scavone, Cristina et al.. Reporting patterns of suicide- and self-injury-related events involving liraglutide, semaglutide, and tirzepatide: data from the European pharmacovigilance database.. Frontiers in pharmacology. 2026.
Mohamed Abdalla, Samih Abdelmutalab et al.. Comparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review.. Cureus. 2026.
Waki, Hironori et al.. Changes in Abdominal Adiposity and Associations With Metabolic Health Markers Following Tirzepatide in Japanese Participants With Obesity Disease: Results From the SURMOUNT-J Study.. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2026.
Tu, Cheng-Yun et al.. Association of tirzepatide versus Glucagon-Like Peptide-1 receptor agonists with oral and periodontal outcomes in patients with type 2 Diabetes: A Global propensity Score-Matched cohort study.. Diabetes research and clinical practice. 2026.
AlAraibi, Ahmed J et al.. The effects of tirzepatide and semaglutide on clinical and metabolic outcomes in patients with heart failure with preserved ejection fraction and obesity: a systematic review and meta-analysis.. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2026.
Lin, Chih-Lang et al.. Tirzepatide versus GLP-1 receptor agonists and stroke in patients with atrial fibrillation and type 2 diabetes.. Nature communications. 2026.
Ciudin, Andreea et al.. Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes.. International journal of obesity (2005). 2026.
Rivera Gutierrez, Rene de J et al.. Cardiometabolic and atherosclerotic cardiovascular disease outcomes associated with tirzepatide: insights from a 1-year multicenter observational study.. Journal of the Endocrine Society. 2026.
Aronne, Louis J et al.. Evaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetes.. Obesity pillars. 2026.
Al-Nusair, Mohammed et al.. Cardiovascular outcomes with tirzepatide versus semaglutide in type 2 diabetes.. Journal of diabetes and metabolic disorders. 2026.
Sehtman-Shachar, Dvora R et al.. Kidney Outcomes With GLP-1 Receptor Agonists and Tirzepatide Versus Finerenone in Type 2 Diabetes and Chronic Kidney Disease: A Real-World Cohort Study.. Diabetes, obesity & metabolism. 2026.
Kuo, Chia-Yu et al.. Tirzepatide versus other anti-diabetic agents for the prevention of diabetic foot complications in patients with type 2 diabetes.. Frontiers in pharmacology. 2026.
Dziewierz, Artur et al.. Tirzepatide persistence, adherence, and dose escalation in a real-world setting with high out-of-pocket costs: a Polish cohort study.. Advances in medical sciences. 2026.
Eisa, Naseem et al.. Effects of tirzepatide (GIP/GLP-1 dual receptor agonist) on cardiorenal biomarkers and functional capacity in heart failure: a systematic review and meta-analysis.. The Journal of clinical endocrinology and metabolism. 2026.
Nicholls, Stephen J et al.. Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis.. European journal of preventive cardiology. 2026.
Dix, Sophie et al.. Real-World Treatment Patterns and Weight Outcomes Before and After a Tirzepatide Price Increase in Over One Million Self-Paying UK Adults With Overweight or Obesity.. Diabetes, obesity & metabolism. 2026.
Jang, Rachelle et al.. GLP-1-based therapies in cardiovascular disease: outcomes, mechanisms, and emerging clinical applications.. European journal of clinical pharmacology. 2026.
Hsu, Wan-Hsuan et al.. Tirzepatide versus other glucose-lowering therapies and risk of COPD exacerbations in patients with comorbid type 2 diabetes: a retrospective cohort study.. Frontiers in pharmacology. 2026.
Study findings are generated with AI assistance and have not been reviewed by a clinician. The date on each finding records when it was added to this monitor; it is not the publication date or a clinical review date.
This monitor does not offer individual treatment advice. Bring personal health questions to a qualified clinician.
Download the findings and bibliography displayed in this page snapshot. Values and confidence intervals remain as reported text; this is not a pooled estimate or a systematic review. Product-label observations and editorial takeaways are excluded.
These findings may omit evidence or contain errors and have not been reviewed by a clinician. A citation or download does not establish source verification. Read the original studies for their methods and limitations.
“Added” dates record entry into the monitor, not publication or clinical review. A null original acquisition or derivation means its historical record is unknown; a current record or verification has its own observation time. The SHA-256 snapshot identifier binds the downloadable public fields. CSV includes finding rows and bibliography-only source rows; JSON includes both lists. Spreadsheet-sensitive CSV cells begin with an apostrophe for safety; JSON preserves the original text.
For attribution, cite ModernDoc and the page URL, data update date and snapshot identifier in the download. Original studies retain their own rights; this download does not grant a licence to their full text.
Get a summary twice a month when this evidence changes
A short summary twice a month, when study findings on this topic change. If nothing changed, we don't email. Summaries use automated source and retraction checks and have not been reviewed by a clinician. No marketing. Subscribing covers GLP-1 receptor agonists, including its related monitor pages.
We'll first send one confirmation email — you're not subscribed until you click it. Subscribing signals an interest in GLP-1 receptor agonists; we treat that as sensitive: we store only your email address, this topic and the date you subscribed, never linked to any health record, and never sold. Temporary abuse counters use keyed identifiers and expire within 24 hours. Our email provider delivers the messages. Every email includes a one-click unsubscribe link. Sent by ModernDoc (moderndoc.co).